IMPACT OF THE SELECTIVITY AND HALF-LIFE OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS ON THE DEVELOPMENT OF SUBCLINICAL KIDNEY INJURY

Objective: to investigate the impact of the selectivity and half-life of nonsteroidal anti-inflammatory drugs (NSAIDs) on the development of subclinical kidney injury (SKI). A standard physical examination was made.

Patients and methods. The study included 80 patients with a verified rheumatoid arthritis (RA) diagnosis. The patients filled in a specially designed questionnaire to explore a history of drug use. As markers of SKI, the investigators determined the concentrations of albumin, α1-microglobulin (α1-MG), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) in urine. A control group consisted of 20 apparently healthy individuals matched for age and gender.

Results. 80 patients suffering from RA received drug therapy. Of them, 82.5% and 87.5% took NSAIDs and disease-modifying antirheumatic drugs, respectively. The levels of SKI markers were compared in three groups of the examinees: 1) NSAID-treated patients; 2) NSAID-untreated patients; 3) a control group. There were statistically significant differences between all the groups (p<0.05). Comparison of the levels of SKI markers revealed no statistically significant difference in the groups receiving selective cyclooxygenase-2 (COX-2) inhibitors (n=18.6%), in those taking nonselective ones (n=68.6%), and the control group. Comparison of the levels of SKI markers demonstrated significantly higher >< 0.05). Comparison of the levels of SKI markers revealed no statistically significant difference in the groups receiving selective cyclooxygenase-2 (COX-2) inhibitors (n=18.6%), in those taking nonselective ones (n=68.6%), and the control group. Comparison of the levels of SKI markers demonstrated significantly higher α1-MG levels in the long-acting NSAID groups (n=8.6%) than in the short-acting NSAID group (n=80%). ALT, ALP, and microalbuminuria showed a similar trend that failed to reach statistical significance.

Conclusion: NSAIDs remain a group of medications with a certain nephrotoxic effect. At the same time, the design of selective COX-2 inhibitors has failed to solve the problem of nephrotoxicity. NSAIDs with long half-lives are characterized by greater nephrotoxicity. The available data provide preconditions for the more differentiated use of NSAIDs, particularly in patients with RA.

1. Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression. Kidney Int. 1997 Jan;51(1):2-15.

2. Schiff MH, Whelton A. Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis. Semin Arthritis Rheum. 2000 Dec;30(3):196-208.

3. Kömhoff M, Grone HJ, Klein T, et al. Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function. Am J Physiol. 1997 Apr;272 (4 Pt 2):F460-8.

4. Khan KN, Paulson SK, Verburg KM, et al. Pharmacology of cyclooxygenase-2 inhibition in the kidney. Kidney Int. 2002 Apr;61(4): 1210-9.

5. Rodriguez F, Llinas MT, Gonzalez JD, et al. Renal changes induced by a cyclooxygenase-2 inhibitor during normal and low sodium intake. Hypertension. 2000 Aug;36(2): 276-81.

6. Rossat J, Maillard M, Nussberger J, et al. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther. 1999 Jul; 66(1):76-84.

7. Henry D, Page J, Whyte I, et al. Consumption of non-steroidal anti-inflammatory drugs and the development of functional renal impairment in elderly subjects. Results of a case-control study. Br J Clin Pharmacol. 1997 Jul;44(1):85-90.

8. Cline DM. Chronic pain: evaluation and treatment in the emergency department. In: Greenfield RH, editor. Managing Pain and End-of-Life Issues. Atlanta: AHC Media LLC; 2007. P. 67-84.

9. Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/ European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010 Sep;69(9):1580-8. doi:10.1136/ard.2010.138461.

10. Walter RB, Milano F, Brasky TM, et al. Long-term use of acetaminophen, aspirin, and other nonsteroidal anti-inflammatory drugs and risk of hematologic malignancies: results from the prospective Vitamins and Lifestyle (VITAL) study. J Clin Oncol. 2011 Jun 10;29(17):2424-31. doi:10.1200/JCO.2011.34.6346. Epub 2011 May 9.

11. Su T, Zhang L, Li X, et al. Regular use of nephrotoxic medications is an independent risk factor for chronic kidney disease-results from a Chinese population study. Nephrol Dial Transplant. 2011 Jun;26(6):1916-23. doi:10.1093/ndt/gfq679. Epub 2010 Nov 8.

12. Izzedine H, Launay-Vacher V, Karie S, et al. Is low-dose methotrexate nephrotoxic? Case report and review of the literature. Clin Nephrol. 2005 Oct;64(4):315-9.

13. Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist. 2006 Jun;11(6): 694-703.

14. Harirforoosh S, Jamali F. Renal adverse effects of non-steroidal anti-inflammatory drugs. Expert Opin Drug Saf. 2009 Nov;8(6):669-81. doi:10.1517/14740330903311023.

15. Harirforoosh S, Asghar W, Jamali F. Adverse Effects of Nonsteroidal Antiinflammatory Drugs: An Update of Gastrointestinal, Cardiovascular and Renal Complications. J Pharm Pharm Sci. 2013; 16(5):821-47.

16. Чельцов ВВ. НПВП-нефропатии. Клиническая нефрология. 2011;(5):7–23. [Chel'tsov VV. NSAID nephropathy. Klinicheskaya nefrologiya. 2011;(5):7-23. (In Russ.)].

17. Mö ller B, Pruijm M, Adler S, et al. Swiss Clinical Quality Management in Rheumatic Diseases (SCQM) Foundation, CH-8048 Zurich, Switzerland.. Chronic NSAID use and long-term decline of renal function in a prospective rheumatoid arthritis cohort study. Ann Rheum Dis. 2015 Apr;74(4): 718-23. doi:10.1136/annrheumdis-2013-204078. Epub 2013 Dec 19.

18. Nderitu P, Doos L, Jones PW, et al. Non-steroidal anti-inflammatory drugs and chronic kidney disease progression: a systematic review. Fam Pract. 2013 Jun;30(3):247-55. doi:10.1093/fampra/cms086. Epub 2013 Jan 8.

19. Winkelmayer WC, Waikar SS, Mogun H, et al. Nonselective and cyclooxygenase-2selective NSAIDs and acute kidney injury. Am J Med. 2008 Dec;121(12):1092-8. doi:10.1016/j.amjmed.2008.06.035.